Compare KRNT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | RIGL |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.1M | 683.2M |
| IPO Year | 2015 | 2000 |
| Metric | KRNT | RIGL |
|---|---|---|
| Price | $15.82 | $34.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $19.75 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 405.9K | 287.6K |
| Earning Date | 02-11-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $208,200,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $4.28 | $66.37 |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | ★ N/A | $5.54 |
| Revenue Growth | 2.15 | ★ 79.13 |
| 52 Week Low | $11.93 | $15.50 |
| 52 Week High | $30.03 | $52.24 |
| Indicator | KRNT | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 43.10 |
| Support Level | $14.23 | $33.23 |
| Resistance Level | $17.96 | $34.99 |
| Average True Range (ATR) | 0.73 | 1.46 |
| MACD | 0.35 | 0.15 |
| Stochastic Oscillator | 67.74 | 43.31 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.